|
|
|
| In this presentation from the February 2024 OPCU event, Mabion, a biologics CDMO with end-to-end services focusing on recombinant proteins development and production, showcases their new installations in upstream development, bioreactors, and downstream development and fill/finish. This state-of-the-art EU-GMP-certified facility is staffed by a team of 250 professionals and as of 2023 is focused solely on providing CDMO services to its clients. Watch now. |
|
|
|
|
A conversation with members of BioPhorum | We spoke to three long-standing members of BioPhorum’s Risk and Business Continuity Workstream about their companies’ approaches to risk management, supply chain continuity, and what they learned from the pandemic. Among them are Melinda McCants, senior resiliency officer at Amgen. |
|
|
|
By Kerim Ozbilge, EY | To address today's challenges and other headwinds, pharma/biotech organizations and CMO/CDMO partners need to re-evaluate and improve externalized operating models. Consider further investing in digitalizing collaboration processes as part of operational excellence and digital transformation road map efforts. |
|
|
|
By Geoff Weiss, Custom Chromatography Research | Going green is virtually impossible for biopharma companies with legacy systems, but going greener might be within reach. Here are some ideas to get started. |
|
|
|
| Development And Regulation Of Veterinary Monoclonals | White Paper | By Adam Tuszyner, Mabion | Although veterinary mAbs have achieved commercial success, ongoing discussions and clinical developments surrounding them are expected to outline a clear regulatory pathway in the near future. |
|
|
| Regulatory Considerations For Alternative Microbial Methods | White Paper | MilliporeSigma | We discuss regulatory expectations for the incorporation of alternative methods to prevent, remove, and detect contaminants focusing on comparability and strategies for easier substitution of current methods. |
|
|
|
|
|
|
|
|
|
|
|
